ArticleHeadache2026
Online interest in calcitonin gene-related peptide-therapies: An infodemiology study using Google trends.
Article in Headache, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate changes in public interest in calcitonin gene-related peptide therapies associated with major product lifecycle milestones using online search data from the United States and Europe.
backgroundCalcitonin gene-related peptide therapies have transformed migraine treatment, but the impact of key product lifecycle milestones on public awareness remains unclear. As patients increasingly turn to online platforms for health information, events such as trial publications, regulatory approvals, commercial launches, and advertising campaigns may drive search activity and signal broader awareness.
methodsWe conducted a retrospective ecological infodemiology study using a quasi-experimental interrupted time-series design with monthly Google Trends data (January 2017-July 2025). Search volume index (0-100 scale) was assessed for seven CGRP-therapies. Milestone events (trial publications, regulatory approvals, commercial launches, and media exposure) were defined a priori as potential drivers of digital impact. We evaluated immediate and sustained changes in search interest following major milestones over time. The primary analysis included all therapies in the United States; secondary analyses evaluated erenumab across five European countries (Germany, France, Italy, Spain, and United Kingdom).
resultsIn the United States, commercial launch was associated with significant immediate increases in search interest for erenumab (β = 102.54; 95% confidence interval [CI], 17.05-188.02, p = 0.021) and galcanezumab (brand search term) (β = 42.36; 95% CI, 15.80-68.91, p = 0.002). Sustained post-launch growth was observed for fremanezumab (brand search term) (β = +0.50/month; 95% CI, 0.27-0.73, p < 0.001), eptinezumab (β = +0.45/month; 95% CI, 0.26-0.64, p < 0.001), rimegepant (brand search term) (β = +0.97/month; 95% CI, 0.47-1.47, p < 0.001), atogepant (brand search term) (β = +1.28/month; 95% CI, 0.70-1.85, p < 0.001), and ubrogepant (brand search term) (β = +0.59/month; 95% CI, 0.42-0.77, p < 0.001). Media exposure was associated with significant immediate increases for erenumab (β = 94.33; 95% CI, 11.17-177.50, p = 0.029) and ubrogepant (β = 29.77; 95% CI, 11.12-48.41, p = 0.003). Regulatory approvals and trial publications were not consistently associated with significant changes in search interest. In Europe, commercial launch was associated with significant immediate increases for erenumab (generic search term) in Italy (β = 126.82; 95% CI, 62.12-191.52, p < 0.001), erenumab (brand search term) in Italy (β = 142.98; 95% CI, 23.88-262.08, p = 0.021) and the United Kingdom (β = 69.44; 95% CI, 6.71-132.16, p = 0.033). Post-launch trends were generally negative across countries, indicating gradual declines after initial spikes.
conclusionsCommercial launch was the most consistent driver of public search interest in CGRP-targeting therapies. Media exposure produced additional increases in selected cases, whereas regulatory approvals and clinical trial publications had limited measurable impact. These findings underscore the dominant role of commercial and consumer-facing communication in shaping public awareness of new migraine treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.